[Sex differences in cardiovascular drug targeting]

Area of Science:

• Pharmacology
• Physiology
• Biochemistry

Context:

• Significant physiological differences exist between men and women, including body size, composition, and kidney function.
• Drug metabolism is influenced by sex-specific variations in primary drug-metabolizing enzymes, particularly the cytochrome P450 family in the liver and intestinal wall.

Purpose:

• To highlight the critical sex-based differences in drug metabolism and response.
• To underscore the importance of considering sex as a biological variable in pharmacokinetics and pharmacodynamics.

Summary:

• Women and men exhibit distinct drug needs and metabolic profiles, impacting drug efficacy and safety.
• Observed sex differences include altered metabolism of substrates like beta-blockers and calcium channel blockers, leading to varied plasma levels and side effect profiles.
• Specific examples include digitalis overdosing in women, higher beta-blocker plasma levels in women, increased ACE inhibitor side effects in women, and differential effects of acetylsalicylic acid on stroke versus myocardial infarction prevention between sexes.
• Anticoagulants, thrombolytics, and QT-prolonging drugs also present sex-specific risks, such as bleeding complications and arrhythmias in women.

Impact:

• Emphasizes the need for sex-specific considerations in drug development, clinical trials, and therapeutic guidelines.
• Highlights the importance of post-approval drug monitoring to identify and manage sex-based adverse events.
• Promotes personalized medicine approaches by accounting for biological sex in pharmacotherapy.